Norbert Vey

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi request reprint Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
    Mohamad Mohty
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Blood 102:470-6. 2003
  2. doi request reprint Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?
    Norbert Vey
    Institut Paoli Calmettes and Aix Marseille Université, Marseille, France
    Interdiscip Top Gerontol 38:73-84. 2013
  3. ncbi request reprint Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution
    N Vey
    Department of Hematology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, 13273 Marseille Cedex 9, France
    Bone Marrow Transplant 33:177-82. 2004
  4. ncbi request reprint The benefit of induction chemotherapy in patients age > or = 75 years
    Norbert Vey
    Department of Hematology, Institut Paoli Calmettes, Marseille, France
    Cancer 101:325-31. 2004
  5. ncbi request reprint Arsenic trioxide for the treatment of myelodysplastic syndromes
    Norbert Vey
    Department d Haematologie, Institut Paoli Calmettes, Marseille, France
    Expert Opin Pharmacother 5:613-21. 2004
  6. ncbi request reprint Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study
    Norbert Vey
    Institut Paoli Calmettes, Marseille, France
    J Clin Oncol 24:2465-71. 2006
  7. ncbi request reprint Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study
    N Vey
    Departement of Hematology, The Institut Paoli Calmettes, Marseille, France
    Leukemia 20:2155-61. 2006
  8. ncbi request reprint Cloretazine for the treatment of acute myeloid leukemia
    Norbert Vey
    Department of Hematology, Institut Paoli Calmettes, 232 Blvd Sainte Marguerite, 13009 Marseille, France
    Expert Rev Anticancer Ther 6:321-8. 2006
  9. doi request reprint Laromustine (cloretazine)
    Norbert Vey
    Unité d Hématologie 3, Institut Paoli Calmettes, Department of Hematology, 232 Blvd Sainte Marguerite, 13009 Marseille, France
    Expert Opin Pharmacother 11:657-67. 2010
  10. ncbi request reprint Simultaneous occurrence of kaposi's sarcoma and chronic myelogenous leukemia
    N Vey
    Institut Paoli Calmettes, Centre Regional de Lutte Contre le Cancer, Universite de la Mediterranee, Marseille France
    Leuk Lymphoma 41:425-8. 2001

Detail Information

Publications99

  1. ncbi request reprint Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
    Mohamad Mohty
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Blood 102:470-6. 2003
    ..Collectively, these results provide a framework for the refinement of RIC approaches designed to enhance the GVT effect with an acceptable risk of GVHD...
  2. doi request reprint Targeting age-related changes in the biology of acute myeloid leukemia: is the patient seeing the progress?
    Norbert Vey
    Institut Paoli Calmettes and Aix Marseille Université, Marseille, France
    Interdiscip Top Gerontol 38:73-84. 2013
    ..An overview of the studies that have evaluated comorbidities and results of geriatric assessments in these patients are also presented...
  3. ncbi request reprint Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution
    N Vey
    Department of Hematology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, 13273 Marseille Cedex 9, France
    Bone Marrow Transplant 33:177-82. 2004
    ..They show that use of PBSC is associated to very low mortality rate and acceptable morbidity and contributes to an improvement of autotransplant results...
  4. ncbi request reprint The benefit of induction chemotherapy in patients age > or = 75 years
    Norbert Vey
    Department of Hematology, Institut Paoli Calmettes, Marseille, France
    Cancer 101:325-31. 2004
    ..The authors conducted a retrospective study comparing the outcomes among these elderly patients with the outcomes among younger patients to assess the impact of intensive treatment approaches in this age group...
  5. ncbi request reprint Arsenic trioxide for the treatment of myelodysplastic syndromes
    Norbert Vey
    Department d Haematologie, Institut Paoli Calmettes, Marseille, France
    Expert Opin Pharmacother 5:613-21. 2004
    ..The current data are presented and discussed in this review...
  6. ncbi request reprint Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study
    Norbert Vey
    Institut Paoli Calmettes, Marseille, France
    J Clin Oncol 24:2465-71. 2006
    ..Evaluation of the safety and efficacy of arsenic trioxide in patients with myelodysplastic syndromes (MDS)...
  7. ncbi request reprint Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study
    N Vey
    Departement of Hematology, The Institut Paoli Calmettes, Marseille, France
    Leukemia 20:2155-61. 2006
    ..Allogeneic SCT should thus be offered in first CR to patients with t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4. New therapeutic approaches are needed for patients without donor...
  8. ncbi request reprint Cloretazine for the treatment of acute myeloid leukemia
    Norbert Vey
    Department of Hematology, Institut Paoli Calmettes, 232 Blvd Sainte Marguerite, 13009 Marseille, France
    Expert Rev Anticancer Ther 6:321-8. 2006
    ..Cloretazine is a promising new antileukemic agent that may be incorporated into an intensive combination regimen...
  9. doi request reprint Laromustine (cloretazine)
    Norbert Vey
    Unité d Hématologie 3, Institut Paoli Calmettes, Department of Hematology, 232 Blvd Sainte Marguerite, 13009 Marseille, France
    Expert Opin Pharmacother 11:657-67. 2010
    ..In these situations, there is at present no standard of care, and new drugs are urgently needed...
  10. ncbi request reprint Simultaneous occurrence of kaposi's sarcoma and chronic myelogenous leukemia
    N Vey
    Institut Paoli Calmettes, Centre Regional de Lutte Contre le Cancer, Universite de la Mediterranee, Marseille France
    Leuk Lymphoma 41:425-8. 2001
    ..Since no immune deficiency could be documented in the patient, this rare observation suggests that CML may have triggered the onset of SK through cytokine release...
  11. ncbi request reprint Survey of early disapearance of BCR/ABL fusion transcript after allogeneic or autologous stem cell transplantation for chronic myelogenous leukemia
    N Vey
    Department of Hematology, Institut Paoli Calmettes and Université de la Mediterranée, Marseille, France
    Leuk Lymphoma 42:945-52. 2001
    ..This suggests that the GVL effect might be operational early during the first weeks following transplantation...
  12. ncbi request reprint [Current management of myelodysplastic syndromes]
    Norbert Vey
    Departement d Hematologie, Institut Paoli Calmettes, 13009 Marseille
    Rev Prat 60:1416-9. 2010
    ..However, for the vast majority, demethylating agents and namely 5-azacytidine currently represent the standard of care. Patient information and participation in clinical trails are important aspects of the current management of MDS...
  13. pmc Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
    Julien Rocquain
    Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 10:401. 2010
    ..Gene mutation is an important mechanism of myeloid leukemogenesis. However, the number and combination of gene mutated in myeloid malignancies is still a matter of investigation...
  14. doi request reprint A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
    Raynier Devillier
    Département d Onco Hématologie, Institut Paoli Calmettes, Unite de Transplantation et de Therapie Cellulaire, F 13273, Marseille, France Aix Marseille Université, F 13007, Marseille, France Inserm UMR1068, Centre de Recherche en Cancérologie de Marseille CRCM, F 13009, Marseille, France
    Am J Hematol 89:83-7. 2014
    ..We conclude that the FBx-ATG regimen results in low incidences of NRM and GVHD in both MUD and the MMUD recipients...
  15. ncbi request reprint Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia
    Didier Blaise
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille Cedex 09, France
    Haematologica 92:533-41. 2007
    ..The aim of this review is to analyze the available research evidence in this field...
  16. doi request reprint Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases
    Roberto Crocchiolo
    Department of Hematology and Medical Oncology, Paoli Calmettes Institute, Marseille, France
    Cancer 119:986-92. 2013
    ..ATG plays a pivotal role in the prevention of graft-versus-host disease (GvHD), but it is associated with a higher relapse rate and an elevated incidence of infections when high doses are used...
  17. ncbi request reprint CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Mohamad Mohty
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Exp Hematol 32:1097-102. 2004
    ..It has been shown that antithymocyte globulin (ATG) dose infused during RIC is a major determinant for the likelihood of developing aGVHD. The ATG modulation on aGVHD is likely related to in vivo T-cell depletion...
  18. pmc Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    Haematologica 98:576-83. 2013
    ....
  19. doi request reprint Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
    Mandy Brecqueville
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    Genes Chromosomes Cancer 51:743-55. 2012
    ..We found a high incidence of ASXL1 mutation in MF patients (20%) and a low incidence in PV (7%) and ET (4%) patients. Mutations in the other genes were rare (CBL, DNMT3A, IDH2, MPL, SF3B1, SUZ12, NF1) or absent (IDH1)...
  20. ncbi request reprint Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation
    Mohamad Mohty
    Departement d Oncologie Medicale, Laboratoire d Immunologie des Tumeurs, Unité de Transplantation et de Thérapie Cellulaire UTTC, Marseille, France
    Blood 106:4407-11. 2005
    ..001). These findings, reconstituting a T(H)1 loop, support a model in which aGVHD reflects a type 1 alloreaction after RIC allo-SCT...
  21. ncbi request reprint Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience
    Eric Jourdan
    Departement d Hematologie, Hopital Caremeau, Centre hospitalier universitaire CHU, Nimes, France
    J Clin Oncol 23:7676-84. 2005
    ..We analyzed the impact of allogeneic stem-cell transplantation (alloSCT) as an early consolidation for young patients with acute myeloblastic leukemia in first complete remission (CR1) through four successive protocols...
  22. doi request reprint Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies
    Didier Blaise
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France
    Exp Hematol 38:1241-50. 2010
    ..No randomized controlled trials have been performed resulting in determining effectiveness on phase II studies, which rarely report on long-term survival...
  23. doi request reprint ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Universite de la Mediterranee Aix Marseille II, Marseille, France
    Br J Haematol 151:365-75. 2010
    ..The overall survival of ASXL1 mutated patients was lower than that of unmutated patients...
  24. doi request reprint Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia
    Raynier Devillier
    Hematology Department, Institut Paoli Calmettes, Marseille, France
    Leuk Lymphoma 54:1228-34. 2013
    ..In selected patients salvage chemotherapy produces CRs, but these are short lived. Other strategies aiming at modulating immune antileukemic activity have to be developed...
  25. ncbi request reprint Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment
    Didier P Blaise
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Cancer 104:1931-8. 2005
    ..Thirty-three patients (median age 52; range 26-60) with acute myeloblastic leukemia (AML) were included in a pilot study of allogeneic stem cell transplantation (Allo-SCT) following a reduced-intensity conditioning (RIC)...
  26. doi request reprint Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations
    Raynier Devillier
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR INSERM, Institut Paoli Calmettes, Marseille, France
    Am J Hematol 87:659-62. 2012
    ..84%, P = 0.009). Our study showed that MRC-AML as defined in the WHO 2008 classification presents a specific mutation pattern characterized by a high frequency of ASXL1 mutations and a low rate of NPM1, FLT3, and DNMT3A mutations...
  27. doi request reprint Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes
    Thomas Prebet
    Hematology Department, Institut Paoli Calmettes and Aix Marseille Université, Marseille, France
    Leuk Res 38:29-33. 2014
    ..We conclude that this combination is tolerable and concomitant administration might be less toxic and have better therapeutic effect (clinicaltrials.gov NCT00776503)...
  28. ncbi request reprint Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
    Anne Etienne
    Department of Hematology, Paoli Calmettes Institute, Marseille, France
    Cancer 109:1376-83. 2007
    ..The objective of this study was to determine the prognostic role of comorbidities in this population...
  29. ncbi request reprint Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen
    Catherine Faucher
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Exp Hematol 31:873-80. 2003
    ..RIC has been shown to allow engraftment with minimal early transplant-related mortality (TRM). However, in the context of RIC, the use of bone marrow (BM) as stem cell source is still little evaluated...
  30. doi request reprint Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation
    Thomas Prebet
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Departement d Hematologie, Institut Paoli Calmettes, Marseille Cedex, France
    Exp Hematol 38:55-60. 2010
    ..The aim of this retrospective study was to assess platelet transfusion needs and the kinetics and predictive factors for platelet recovery after reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT)...
  31. doi request reprint A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
    Hugues de Lavallade
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, Institut Paoli Calmettes and Inserm UMR891, Marseille, France
    Leuk Res 34:254-7. 2010
    ..These findings may prove useful for identifying at the time of diagnosis a subset of CP-CML patients who are likely to be resistant to imatinib and require an alternative treatment...
  32. doi request reprint Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience
    Jean El-Cheikh
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Exp Hematol 41:17-27. 2013
    ....
  33. doi request reprint Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction
    Thomas Prebet
    Department of Hematology, Institut Paoli Calmettes, Marseille, France
    Leuk Lymphoma 53:2186-91. 2012
    ..This work shows that the substitution of an anthracycline by topotecan is feasible and associated with significant efficacy for patients with AML with persistent leukemia at day 14 after standard-dose anthracycline induction...
  34. doi request reprint Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study
    Thomas Prebet
    Department of Hematology, Paoli Calmettes Institute, Marseille, France
    Cancer 117:974-81. 2011
    ..Various combination regimens of GO have been developed, but few data are available regarding their efficacy compared with IHDAraC-based regimens...
  35. doi request reprint The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myel
    Anne Wanquet
    a Département d Onco Hématologie, Institut Paoli Calmettes, Marseille, France
    Leuk Lymphoma 57:2315-20. 2016
    ..NRM was 3% and 17% at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients. ..
  36. doi request reprint Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation
    Raynier Devillier
    Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France Aix Marseille Université, Marseille, France Inserm UMR 1068 Centre de Recherche en Cancérologie de Marseille, Marseille, France Electronic address
    Biol Blood Marrow Transplant 20:1560-5. 2014
    ..Attempts to improve leukemic control with UCB Allo-HSCT are warranted, as well as the evaluation of other alternative donors in this context. ..
  37. doi request reprint Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup
    Thomas Prebet
    Institut Paoli Calmettes, 13009 Marseille, France
    J Clin Oncol 27:4747-53. 2009
    ..In elderly patients, these AML types are rare, and intensive treatments are much less tolerated. We conducted a retrospective study to evaluate the characteristics and outcome of AML with t(8;21) or inv(16) in the elderly...
  38. doi request reprint A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
    Norbert Vey
    Institut Paoli Calmettes, Marseille, France
    Blood 120:4317-23. 2012
    ..We conclude that IPH2101 administration is safe and can block KIR for prolonged periods of time with limited side effects. Registered with the European Union Drug Regulating Authorities Clinical Trials (EUDRACT) as 2005-005298-31...
  39. doi request reprint Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or U
    Didier Blaise
    Transplant and Cellular Therapy Unit, Institut Paoli Calmettes, Marseille, France Hematology Department, Institut Paoli Calmettes, Marseille, France Centre de Recherche en Cancérologie de Marseille CRCM, Marseille, France Aix Marseille University AMU, Marseille, France Electronic address
    Biol Blood Marrow Transplant 22:119-24. 2016
    ..We conclude that T cell-replete haplo-ID HSCT followed by post-transplantation high-dose- cyclophosphamide in patients over 55 years is associated with promising results, similar to MRD HSCT, and is deserving prospective evaluation...
  40. doi request reprint Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease
    Raynier Devillier
    Hematology Department, Transplantation Program, Institut Paoli Calmettes, Marseille, France Aix Marseille Université, Marseille, France Centre de Recherche en Cancérologie de Marseille CRCM, Marseille, France
    Biol Blood Marrow Transplant 20:370-4. 2014
    ..It represents a valuable platform for developing further post-transplantation strategies aimed at reducing the incidence of relapse, particularly in the setting of high-risk disease...
  41. doi request reprint Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia
    Jean Valère Malfuson
    Department of Hematology, Hôpital d Instruction des Armées, Clamart, France
    Haematologica 93:1806-13. 2008
    ..The aim of the present study was to analyze the decisional value of poor risk factors in 416 elderly patients treated in the ALFA-9803 trial in order to derive a decisional index...
  42. ncbi request reprint [Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches]
    Mohamad Mohty
    Laboratoire d Immunologie des Tumeurs, Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, 232, boulevard de Sainte Marguerite, 13273 Marseille, France
    Bull Cancer 90:751-7. 2003
    ..We here review recently published observations in this field, and propose new vaccine programs that use autologous AML blasts differentiated into dendritic cells...
  43. doi request reprint [Perception by cancer patients of biomedical research in the era of large-scale biobanking]
    Julien Mancini
    Aix Marseille Univ, UMR 912, 13009, Marseille, France
    Med Sci (Paris) 28:28-32. 2012
    ..Patients are globally expressing a wish for more proposals to participate in research in collaboration with scientific teams...
  44. ncbi request reprint Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study
    Vahid Asnafi
    Department of Hematology, Necker Enfants Malades, Saint Louis, France
    Blood 105:3072-8. 2005
    ..Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs...
  45. doi request reprint The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome
    Thomas Prebet
    INSERM U891, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Blood 116:2315-23. 2010
    ....
  46. pmc Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies
    Claire Oudin
    Departement d Hematologie, Institut Paoli Calmettes, Marseille, France Aix Marseille University, Marseille, France
    Haematologica 99:1762-8. 2014
    ..This well-tolerated conditioning platform can lead to long-term disease control and offers possibilities of modulation according to disease stage or further development. ..
  47. doi request reprint Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertility
    Emmanuelle Assouline
    Department of Oncology, Institut Paoli Calmettes, Marseille, France Electronic address
    Clin Lymphoma Myeloma Leuk 13:704-10. 2013
    ..We evaluated ovarian function and fertility among female patients younger than 35 years who received RIC Allo-SCT for hematological malignancy or aplastic anemia (AA)...
  48. pmc Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
    Raynier Devillier
    Hematology Department, Institut Paoli Calmettes, Marseille, France
    Oncotarget 6:8388-96. 2015
    ..We conclude that ASXL1 and TP53 mutations identify two molecular subgroups among AML-MRCs, with specific poor prognosis. This could be useful for future diagnostic and prognostic classifications. ..
  49. doi request reprint Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies
    Jean El-Cheikh
    Transplantation and Cellular Therapy Unit U2T, Paoli Calmettes Institute, Marseille, France
    Cancer 121:1809-16. 2015
    ..The aim of the current retrospective study was to compare the outcome of patients after haplo and UCB grafts prepared using a nonmyeloablative conditioning regimen...
  50. doi request reprint Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia
    Nathalie Cervera
    Centre de Recherche en Cancerologie de Marseille, Aix Marseille University, Marseille, France Laboratoire d Oncologie Moléculaire, UMR1068 Inserm, CNRS UMR7258, Aix Marseille University, Marseille, France Institut Paoli Calmettes, Aix Marseille University, Marseille, France
    Am J Hematol 89:604-9. 2014
    ..The myeloproliferative class had a worse prognosis than the myelodysplastic class and was impacted by RUNX1 mutations only. Our results argue for a reclassification of CMML based on the myelodysplastic/myeloproliferative status...
  51. ncbi request reprint Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia
    Mohamad Mohty
    Laboratoire d Immunologie des Tumeurs, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13273 Marseille Cedex 09, France
    Blood 103:4666-8. 2004
    ..These findings provide evidence that response to imatinib is capable to restore some DC-related immune functions in CML that might be beneficial for long-term disease control...
  52. ncbi request reprint Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature
    Marie Joelle Mozziconacci
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR599 Inserm, Institut Paoli Calmettes, Marseille, France
    Leuk Res 32:1304-8. 2008
    ..The FGFR1-MPD seems refractory to current chemotherapies and is not sensitive to imatinib. Currently, only the patients with bone marrow transplantation stand a chance of survival...
  53. pmc Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    BMC Cancer 8:299. 2008
    ..Not much is known about the molecular biology of this disease...
  54. ncbi request reprint Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion
    Anne Murati
    Department of Molecular Oncology, Marseille Cancer Institute, UMR599 INSERM and Paoli Calmettes Institute, Marseille, France
    Int J Oncol 26:1485-92. 2005
    ..Although the FGFR1-MPD is rare, its study provides interesting clues to the understanding of hematopoietic stem cell biology and oncogene activation...
  55. doi request reprint Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors
    Jérôme Rey
    INSERM UMR 891, Universite de la Mediterranee, Institut de Cancérologie et d Immunologie de Marseille IFR137, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France
    Trends Mol Med 15:275-84. 2009
    ..Finally, we review future strategies that offer the possibility of enhancing the effector functions of NK and gammadelta T cells against haematological malignancies...
  56. pmc Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
    Thomas Prebet
    Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    J Clin Oncol 29:3322-7. 2011
    ..The outcome of these patients has not yet been described...
  57. ncbi request reprint Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen
    M Mohty
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Leukemia 17:2168-77. 2003
    ..Collectively, these results suggest that prospective efforts are warranted to develop optimal antimicrobial preventive strategies after RIC allo-SCT...
  58. doi request reprint Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
    Sebastien Maury
    From the Département d Hématologie, Hopital Henri Mondor, Assistance Publique Hopitaux de Paris AP HP, Institut Mondor de Recherche Biomédicale équipe 21, Universite Paris Est, Creteil S M, Service de Biostatistique S C and Département d Hématologie N B, K B, H D, Hopital Saint Louis, AP HP, Institut Universitaire d Hematologie, Universite Paris Diderot, Paris, Département d Hématologie X T and Group for Research on Adult Acute Lymphoblastic Leukemia Coordination Office V L, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre Benite, Departement d Hematologie, Centre Hospitalier Universitaire CHU Haut Lévêque, Pessac T L, Departement d Hematologie, Institut Universitaire du Cancer, Toulouse F H, Département d hématologie clinique, CHU Hôtel Dieu P C, and Service d Hématologie Biologique, CHU M C B, Nantes, Departement d Hematologie, CHU, Angers M H, N I, Departement d Hematologie
    N Engl J Med 375:1044-53. 2016
    ..Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial...
  59. doi request reprint Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities
    Anne Wanquet
    Hematology Department, Institut Paoli Calmettes, Marseille, France
    Am J Hematol 90:859-63. 2015
    ..Thus, AML/MDS patients with 3q abnormalities appear to be a heterogeneous group in their response to AZA, and AZA may represent a suitable option in particular as a bridge to allogeneic transplantation...
  60. doi request reprint Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup
    Francoise Huguet
    Department of Hematology, Hopital Purpan, Toulouse, France
    Leuk Lymphoma 56:847-57. 2015
    ..Clofarabine warrants further exploration in advanced ALL treatment and bridge-to-transplant. ..
  61. doi request reprint Azacitidine for the treatment of relapsed and refractory AML in older patients
    Raphael Itzykson
    Departement d Hematologie, Hopital Saint Louis, Assistance Publique des Hôpitaux de Paris AP HP and Université Paris 7, Paris, France
    Leuk Res 39:124-30. 2015
    ..3 months. These results warrant further investigation of azacitidine-based regimens in this subgroup of patients...
  62. ncbi request reprint Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup
    Jacques Delaunay
    Departement of Hematology, Hopital Saint Louis, Paris, France
    Blood 102:462-9. 2003
    ..These results markedly contrast with those reported in patients with t(8;21) AML in whom WBC, and not age, was the main high-risk factor for relapse, DFS, and survival...
  63. doi request reprint Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts
    Julie Gertner-Dardenne
    Institut Paoli Calmettes, Laboratoire d Immunologie des Tumeurs, Marseille F 13009, France
    J Immunol 188:4701-8. 2012
    ..This study enhances the interest of these cells for therapeutic purposes such as AML treatment...
  64. ncbi request reprint Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling
    Norbert Vey
    Department of Molecular Oncology, Institut Paoli Calmettes UMR599 Inserm, IFR137, Marseille Cancer Institute, Marseille, France
    Oncogene 23:9381-91. 2004
    ..Our results demonstrate the transcriptional heterogeneity of NC-AMLs, and suggest the existence of 'translocation-like' NC-AMLs and of a gene expression signature that may predict response to chemotherapy...
  65. doi request reprint [Histone methyltransferases: a new class of therapeutic targets in cancer treatment?]
    Hassiba Chaib
    Centre de Recherche en Cancerologie de Marseille, Marseille, France
    Med Sci (Paris) 27:725-32. 2011
    ..Since their links with pathogenesis and progression of cancer were recognized, histone methyltransferases emerge as promising therapeutic targets in cancer treatment...
  66. doi request reprint A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
    Jean Luc Harousseau
    University Hospital Hotel Dieu, Nantes, France
    Blood 114:1166-73. 2009
    ..The results of this randomized study showed that tipifarnib treatment did not result in an increased survival compared with BSC, including hydroxyurea. This trial was registered at www.clinicaltrials.gov as #NCT00093990...
  67. ncbi request reprint Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: predictive value of prior Hb level
    V Ivanov
    Unit of Transplantation and Cellular Therapy, Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Transfusion 44:501-8. 2004
    ..RBCT (RBCT) requirements of stem cell transplant (SCT) recipients are often substantial and may be related to transplant type...
  68. doi request reprint A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, 69008, Lyon, France
    Curr Med Res Opin 26:2653-60. 2010
    ..Response was also assessed according to baseline characteristics including iron, folate and vitamin B12 status...
  69. ncbi request reprint Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation
    M Mohty
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Bone Marrow Transplant 34:527-30. 2004
    ....
  70. ncbi request reprint The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison
    M Mohty
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, 13273 Marseille, France
    Leukemia 19:916-20. 2005
    ..7-9.6) was the strongest factor significantly predictive of an improved LFS. We conclude that if a matched related donor is identified, RIC-allo-SCT should be proposed for AML patients not eligible for standard myeloablative allo-SCT...
  71. ncbi request reprint Pilot study of immunotherapy with interleukin-2 after autologous stem cell transplantation in advanced breast cancers
    G Gravis
    Oncology Unit, Institut Paoli Calmettes, 232 Bd Sainte Marguerite, 13273 Marseille, France
    Anticancer Res 20:3987-91. 2000
    ..However no clinical beneficial effect was documented for these advanced heavily pretreated breast cancers. Immune modulation with rIL-2 earlier requires further investigation...
  72. ncbi request reprint Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials
    N Dhedin
    Department of Hematology, Hopital Pitie Salpetriere, Paris, France
    Leukemia 20:336-44. 2006
    ..Of interest, the reduced relapse risk after ASCT translated in better disease-free survival in the 300 rapid responders who reached CR after the first induction course...
  73. doi request reprint Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients
    Diane Coso
    Department of Hematology, Institut J Paoli I Calmettes, Universite de la Mediterranee, Marseille, France
    Leuk Lymphoma 55:1849-53. 2014
    ..The matched-control analysis showed no difference for either OS or EFS. LBCL in AYA presents with some critical features which differ from those of older adults. However, the outcome is equivalent to that observed in older patients...
  74. pmc Monocyte deactivation in neutropenic acute respiratory distress syndrome patients treated with granulocyte colony-stimulating factor
    Djamel Mokart
    Department of Anesthesiology and Intensive Care Unit, Paoli Calmette Institute, 232 Bd Sainte Marguerite, 13273 Marseille Cedex 9, France
    Crit Care 12:R17. 2008
    ..In the present study, we tried to characterize in vitro monocyte baseline cytokine production and responsiveness to lipopolysaccharide exposure...
  75. doi request reprint Adherence to leukemia maintenance therapy: a comparative study among children, adolescents, and adults
    Julien Mancini
    School of Medicine, Aix Marseille University, Marseille, France
    Pediatr Hematol Oncol 29:428-39. 2012
    ..Declared nonadherence of leukemia maintenance therapy is not negligible and should be screened at follow-up consultations using three simple questions...
  76. doi request reprint Consent for biobanking: assessing the understanding and views of cancer patients
    Julien Mancini
    Universite d Aix Marseille, Marseille, France
    J Natl Cancer Inst 103:154-7. 2011
    ..We conclude that the opt-in consent procedure is positively perceived by most patients but should be improved for a better understanding and possibly an even better adherence to the consent process...
  77. doi request reprint Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
    Br J Haematol 145:788-800. 2009
    ..These results show that ASXL1 might play the role of a tumour suppressor in myeloid malignancies...
  78. doi request reprint Vorinostat in acute myeloid leukemia and myelodysplastic syndromes
    Thomas Prebet
    Institut Paoli Calmettes, Department of Haematology, 232 Boulevard Sainte Marguerite, 13009 Marseille, France
    Expert Opin Investig Drugs 20:287-95. 2011
    ..Vorinostat is an epigenetic targeted drug belonging to the histone deacetylase (HDAC) inhibitors family. It is the second-generation HDAC inhibitor that has been more extensively studied in AML and MDS...
  79. ncbi request reprint High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation
    J El-Cheikh
    Unite de Transplantation et de Therapie Cellulaire, Institut Paoli Calmettes, Marseille, France
    Bone Marrow Transplant 39:301-6. 2007
    ..This safety data provide support for an efficacy study of this prophylaxis strategy, because this may help further improving the outcome of RIC or nonmyeloablative allo-SCT...
  80. ncbi request reprint [Recent advances in the treatment of myelodysplastic syndromes]
    V Gelsi-Boyer
    Département de biopathologie, 232, boulevard Sainte Marguerite, 13009 Marseille, France
    Rev Med Interne 27:600-9. 2006
    ..FUTURE PROSPECTS AND PROJECTS: The interesting results achieved with these new agents show that it is necessary to continue investigation in order to improve therapeutic strategies in MDS...
  81. ncbi request reprint Transient detection of beta-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapy
    Claude Bagnis
    Institut Paoli Calmettes, Centre Régional de Lutte Contre le Cancer Provence Alpes Côte d Azur, Marseille, France
    Exp Hematol 30:108-15. 2002
    ..The fate of genetically modified cells and their progeny was followed in vivo, after reinfusion in patients treated with high-dose chemotherapy for poor-prognosis breast or ovarian carcinomas...
  82. ncbi request reprint Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38- primitive haematopoietic progenitors
    Mohamad Mohty
    Laboratoire d Immunologie des Tumeurs, Departement d Hematologie, Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Br J Haematol 119:115-8. 2002
    ..The reduced DC numbers may contribute to leukaemia escape from immune control and restoration of DC may be a goal for CML immunotherapy...
  83. ncbi request reprint Features of large granular lymphocytes (LGL) expansion following allogeneic stem cell transplantation: a long-term analysis
    M Mohty
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Leukemia 16:2129-33. 2002
    ..These data suggest that LGL might be a subset of effector lymphocytes which may participate to the graft-versus-tumor effect...
  84. ncbi request reprint Visceral Kaposi's sarcoma associated with human herpesvirus 8 seroconversion in a heart transplant recipient
    F Collart
    Cardiac Surgery Department, Paoli Calmette Institute, Marseille, France
    Transplant Proc 36:3173-4. 2004
    ..Herein we report a case of a heart transplant recipient who had a fatal visceral KS in association with HHV-8 seroconversion at 18 months after transplantation with a donor having positive serology discovered after transplantation...
  85. doi request reprint Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia
    Mélanie Bonnet
    Center of Immunology of Marseille Luminy, Universite de la Mediterranee, Marseille Cedex 9, France
    Blood 117:6650-9. 2011
    ..Altogether, our data lend further support to the significance of therapeutic targeting of MYC and/or the PTEN/AKT pathways, both in GSI-resistant and identified NOTCH1-independent/MYC-mediated T-ALL patients...
  86. ncbi request reprint Large granular lymphocytes (LGL) following non-myeloablative allogeneic bone marrow transplantation: a case report
    M Mohty
    Laboratoire d'Immunologie des Tumeurs, Institut Paoli-Calmettes, , Marseille, France
    Bone Marrow Transplant 28:1157-60. 2001
    ..These observations suggest that LGL are a subset with the properties of effector lymphocytes which may contribute to the graft-versus-tumor effect...
  87. ncbi request reprint Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient
    G Damaj
    Department of Hematology, Institute Paoli Calmettes, 232, boulevard Sainte Marguerite, B P 156, 13273, Marseille Cedex 9, France
    Ann Hematol 83:390-3. 2004
    ..Further permanent caspofungin maintenance with voriconazole added during aplasia periods permitted two consolidation courses and autograft-based intensification without any delay...
  88. ncbi request reprint Single-agent thalidomide induces response in T-cell lymphoma
    G Damaj
    Institut Paoli Calmettes Cancer Center, Marseille, France
    Eur J Haematol 74:169-71. 2005
    ..We report three cases of relapsed refractory T-cell lymphoma treated with thalidomide with a good tumor response...
  89. ncbi request reprint Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, 69437, Lyon Cedex 03, France
    J Clin Oncol 22:4075-86. 2004
    ..We analyzed the benefits of a risk-adapted postremission strategy in adult lymphoblastic leukemia (ALL), and re-evaluated stem-cell transplantation (SCT) for high-risk ALL...
  90. ncbi request reprint A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia
    Francis Giles
    Leuk Res 30:1591-5. 2006
    ..3 months) in the study cohort was directly comparable to that of 233 matched patients treated with other single agents. The study cloretazine regimen had minimal activity in a very high risk subset of patients with relapsed AML...
  91. ncbi request reprint One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission
    Eric Jourdan
    Hopital Caremeau, CHU Nimes, France
    Br J Haematol 129:403-10. 2005
    ..12), 57% and 47% (P = 0.11), 8% and 8% (P = 0.95) for HiDAC 1 and HiDAC 2 groups, respectively. Further studies are warranted with a larger number of patients to test the place of a second course of HiDAC in this setting...
  92. doi request reprint Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group
    Oumedaly Reman
    Centre Hospitalier, Caen, France
    Leuk Res 32:1741-50. 2008
    ..CNS leukemia at first relapse remains of similar poor prognosis than all other adult ALL in first relapse...
  93. ncbi request reprint Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma
    Hugues de Lavallade
    Br J Haematol 135:408-10. 2006
  94. ncbi request reprint Acute leukemia during pregnancy: a report on 37 patients and a review of the literature
    Youcef Chelghoum
    Service d Hematologie Clinique, Hopital Edouard Herriot, Lyon, France
    Cancer 104:110-7. 2005
    ..Acute leukemia (AL) requiring cytotoxic treatment occurring during pregnancy poses a very difficult therapeutic dilemma...
  95. ncbi request reprint Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study
    Catherine Cordonnier
    Hopital Henri Mondor, Creteil, France
    Int J Antimicrob Agents 31:135-41. 2008
    ..For AL, a 10mg/kg weekly dose appears to be well tolerated during chemotherapy and may represent an important tool towards improving AL patient outcome...
  96. ncbi request reprint Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia
    Francis Giles
    The University of Texas M D Anderson Cancer Center, Department of Leukemia, Houston, TX 77030, USA
    J Clin Oncol 25:25-31. 2007
    ..A multicenter phase II study of cloretazine was conducted in patients 60 years of age or older with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)...
  97. ncbi request reprint Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
    Sophie Park
    Service d Hematologie, Hopital Cochin, Assistance Publique des Hopitaux de Paris, Universite Paris, France
    Blood 111:574-82. 2008
    ....
  98. ncbi request reprint Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials
    Emmanuelle Tavernier
    Hopital Nord, Saint Etienne, France
    Cancer 110:2747-55. 2007
    ..Although treatment intensity and outcome were not comparable, with improvements in survival it is important to evaluate the rate and the type of second neoplasms in adults with ALL...
  99. ncbi request reprint Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results
    Arnaud Pigneux
    Service des Maladies du Sang, Hopital du Haut leveque, Avenue de Magellan, 33604 Pessac Cedex, France
    Haematologica 92:1327-34. 2007
    ....